Matthew McCartney1, Sophia Zagora2, Peter McCluskey3
Introduction: With continuing advancements in the treatment of non-infectious Uveitis through intravi- treal steroids, large centres worldwide are assessing the beneﬁts of these therapies, in comparison to established therapies, in view of efﬁcacy, safety and medication load reduction. Our review highlights the experience of a single Australian centre from 2012 to present with Ozurdex, an intravitreal dexa- methasone implant.
Method: Retrospective review of 62 implants placed in 17 eyes of 14 patients with non-infectious uveitis between 2012 and April 2018. All patients commenced on therapy were previously unsuccess- ful with local and/or systemic therapy. The struc- tured post-injection review assessed best-corrected visual acuity (BCVA), optical coherence tomography (OCT) derived central retinal thickness (CRT), adjunct medication reduction and patient satisfaction.
Results: In our cohort, intravitreal dexamethasone demonstrated clinically signiﬁcant stabilisation or improvement in BCVA, improved CRT in 85% of eyes. In addition, a majority of patients either were able to reduce or cease systemic steroid therapy.
Conclusion: While larger studies are required, this review presents Ozurdex as a potentially highly effective treatment option for non-infectious Uveitis, in particular, those cases with cystoid macular oedema.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY